Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: The PRIME study

Journal of Hypertension

Volumn 22, Issue 2, 2004, Pages 415-423

  Blacher, Jacques ^a   Evans, Alun ^b   Arveiler, Dominique ^c   Amouyel, Philippe ^d   Ferrières, Jean ^d   Bingham, Annie ^a   Yarnell, John ^b   Haas, Bernadette ^c   Montaye, Michèle ^d   Ruidavets, Jean Bernard ^d   Ducimetière, Pierre ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Lab d'Epidemiol et de S Pub   (France)

^d INSERM   (France)

Author keywords

Angiotensin converting enzyme inhibitors; Antihypertensive drugs; Beta blockers; Calcium channel antagonists; Coronary risk; Diuretics; Prospective study

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; ANGINA PECTORIS; ARTICLE; ASSOCIATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FOLLOW UP; FRANCE; HEALTH CENTER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IRELAND; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 10744227069     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200402000-00028     Document Type: Article

References (24)

1. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of cardiovascular disease mortality in Europe. Eur Heart J 1997; 18:1231-1248.
2. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 21:293-298.
3. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
4. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
5. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies; a meta-analysis of randomised controlled trials. Lancet 2000; 356:1949-1954.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
7. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
8. Yamell JWG, for the PRIME Study Group. The PRIME Study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Q J Med 1998; 91:667-676.
9. Ducimetière P, Ruidavets JB, Montaye M, Haas B, Yarnell J, on behalf of the PRIME Study Group. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the PRIME Study. Int J Epidemiol 2001; 30:1057-1062.
10. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods, 2nd edition. Geneva: World Health Organization; 1982.
11. Guide National de Prescriptions des Médicaments. Paris: Editions du Vidal; 1991.
12. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992; 12:701-707.
13. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A, for WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates and case fatality in 38 populations from 21 countries in 4 continents. Circulation 1994; 90:583-612.
14. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
15. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317:167-171.
16. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39:105-110.
17. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.
18. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277:739-745.
19. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903-1907.
20. Guidelines Subcommittee. 1999 World Health Organization-Internal Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
22. Frohlich ED. Treating hypertension - what are we to believe? N Engl J Med 2003; 348:639-641.
23. Waddell TK, Dart AM, Medley TL, Cameron JD, Kingwell BA. Carotid pressure is a better predictor of coronary artery disease severity than brachial pressure. Hypertension 2001; 38:927-931.
24. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926.